Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Diagnostic characteristics of supplemental laboratory criteria for incomplete Kawasaki disease in children with complete Kawasaki disease

  • Jun, Hyun Ok (Department of Pediatrics, University of Ulsan College of Medicine) ;
  • Yu, Jeong Jin (Department of Pediatrics, University of Ulsan College of Medicine) ;
  • Kang, So Yeon (Department of Pediatrics, University of Ulsan College of Medicine) ;
  • Seo, Chang Deok (Department of Pediatrics, University of Ulsan College of Medicine) ;
  • Baek, Jae Suk (Department of Pediatrics, University of Ulsan College of Medicine) ;
  • Kim, Young-Hwue (Department of Pediatrics, University of Ulsan College of Medicine) ;
  • Ko, Jae-Kon (Department of Pediatrics, University of Ulsan College of Medicine)
  • Received : 2014.07.25
  • Accepted : 2014.11.04
  • Published : 2015.10.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: In 2004, the American Heart Association (AHA) had published an algorithm for the diagnosis of incomplete Kawasaki disease (KD). The aim of the present study was to investigate characteristics of supplemental laboratory criteria in this algorithm. Methods: We retrospectively examined the medical records of 355 patients with KD who were treated with intravenous immunoglobulin (IVIG) during the acute phase of the disease. Laboratory data were obtained before the initial IVIG administration and up to 10 days after fever onset. In 106 patients, laboratory testing was performed more than twice. Results: The AHA supplemental laboratory criteria were fulfilled in 90 patients (25.4%), and the frequency of laboratory examination (odds ratio [OR], 1.981; 95% confidence interval [CI], 1.391-2.821; P<0.001) was a significant predictor of it. The fulfillment of AHA supplemental laboratory criteria was significantly associated with refractoriness to the initial IVIG administration (OR, 2.388; 95% CI, 1.182-4.826; P=0.013) and dilatation of coronary arteries (OR, 2.776; 95% CI, 1.519-5.074; P=0.001). Conclusion: Repeated laboratory testing increased the rate of fulfillment of the AHA supplemental laboratory criteria in children with KD.

Keywords

References

  1. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, et al. Long-term consequences of Kawasaki disease: a 10-to 21-year follow-up study of 594 patients. Circulation 1996;94:1379-85. https://doi.org/10.1161/01.CIR.94.6.1379
  2. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708-33. https://doi.org/10.1542/peds.2004-2182
  3. Sudo D, Monobe Y, Yashiro M, Mieno MN, Uehara R, Tsuchiya K, et al. Coronary artery lesions of incomplete Kawasaki disease: a nationwide survey in Japan. Eur J Pediatr 2012;171:651-6. https://doi.org/10.1007/s00431-011-1630-3
  4. Manlhiot C, Christie E, McCrindle BW, Rosenberg H, Chahal N, Yeung RS. Complete and incomplete Kawasaki disease: two sides of the same coin. Eur J Pediatr 2012;171:657-62. https://doi.org/10.1007/s00431-011-1631-2
  5. Sonobe T, Kiyosawa N, Tsuchiya K, Aso S, Imada Y, Imai Y, et al. Prevalence of coronary artery abnormality in incomplete Kawasaki disease. Pediatr Int 2007;49:421-6. https://doi.org/10.1111/j.1442-200X.2007.02396.x
  6. Witt MT, Minich LL, Bohnsack JF, Young PC. Kawasaki disease: more patients are being diagnosed who do not meet American Heart Association criteria. Pediatrics 1999;104:e10. https://doi.org/10.1542/peds.104.1.e10
  7. Barone SR, Pontrelli LR, Krilov LR. The differentiation of classic Kawasaki disease, atypical Kawasaki disease, and acute adenoviral infection: use of clinical features and a rapid direct fluorescent antigen test. Arch Pediatr Adolesc Med 2000;154:453-6. https://doi.org/10.1001/archpedi.154.5.453
  8. Falcini F, Cimaz R, Calabri GB, Picco P, Martini G, Marazzi MG, et al. Kawasaki's disease in northern Italy: a multicenter retrospective study of 250 patients. Clin Exp Rheumatol 2002;20:421-6.
  9. Hsieh YC, Wu MH, Wang JK, Lee PI, Lee CY, Huang LM. Clinical features of atypical Kawasaki disease. J Microbiol Immunol Infect 2002;35:57-60.
  10. Perrin L, Letierce A, Guitton C, Tran TA, Lambert V, Kone-Paut I. Comparative study of complete versus incomplete Kawasaki disease in 59 pediatric patients. Joint Bone Spine 2009;76:481-5. https://doi.org/10.1016/j.jbspin.2008.11.015
  11. Minich LL, Sleeper LA, Atz AM, McCrindle BW, Lu M, Colan SD, et al. Delayed diagnosis of Kawasaki disease: what are the risk factors? Pediatrics 2007;120:e1434-40. https://doi.org/10.1542/peds.2007-0815
  12. Chang FY, Hwang B, Chen SJ, Lee PC, Meng CC, Lu JH. Characteristics of Kawasaki disease in infants younger than six months of age. Pediatr Infect Dis J 2006;25:241-4. https://doi.org/10.1097/01.inf.0000202067.50975.90
  13. Yellen ES, Gauvreau K, Takahashi M, Burns JC, Shulman S, Baker AL, et al. Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease. Pediatrics 2010;125: e234-41. https://doi.org/10.1542/peds.2009-0606
  14. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 1989;5: 303-11.
  15. Dallaire F, Dahdah N. New equations and a critical appraisal of coronary artery Z scores in healthy children. J Am Soc Echocardiogr 2011;24:60-74. https://doi.org/10.1016/j.echo.2010.10.004
  16. Burns JC. Kawasaki disease update. Indian J Pediatr 2009;76:71-6. https://doi.org/10.1007/s12098-009-0031-3
  17. Hong CE. Textbook of pediatrics. 10th ed. Seoul: Korea Textbook Publishing Co., 2012
  18. Fukushige J, Takahashi N, Ueda Y, Ueda K. Incidence and clinical features of incomplete Kawasaki disease. Acta Paediatr 1994;83: 1057-60. https://doi.org/10.1111/j.1651-2227.1994.tb12985.x
  19. Fukazawa R. Long-term prognosis of Kawasaki disease: increased cardiovascular risk? Curr Opin Pediatr 2010;22:587-92.
  20. Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2006;114:2710-38. https://doi.org/10.1161/CIRCULATIONAHA.106.179568
  21. Koren G, Lavi S, Rose V, Rowe R. Kawasaki disease: review of risk factors for coronary aneurysms. J Pediatr 1986;108:388-92. https://doi.org/10.1016/S0022-3476(86)80878-2
  22. Daniels SR, Specker B, Capannari TE, Schwartz DC, Burke MJ, Kaplan S. Correlates of coronary artery aneurysm formation in patients with Kawasaki disease. Am J Dis Child 1987;141:205-7.
  23. Kawamura T, Wago M, Kawaguchi H, Tahara M, Yuge M. Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int 2000;42:241-8. https://doi.org/10.1046/j.1442-200x.2000.01225.x
  24. Bang S, Yu JJ, Han MK, Ko HK, Chun S, Choi HS, et al. Log-transformed plasma level of brain natriuretic peptide during the acute phase of Kawasaki disease is quantitatively associated with myocardial dysfunction. Korean J Pediatr 2011;54:340-4. https://doi.org/10.3345/kjp.2011.54.8.340

Cited by

  1. Changes in clinical and laboratory features of Kawasaki disease noted over time in Daejeon, Korea vol.15, pp.1, 2017, https://doi.org/10.1186/s12969-017-0192-y
  2. Suppressed plasmablast responses in febrile infants, including children with Kawasaki disease vol.13, pp.3, 2015, https://doi.org/10.1371/journal.pone.0193539
  3. Clinical implications in laboratory parameter values in acute Kawasaki disease for early diagnosis and proper treatment vol.61, pp.5, 2015, https://doi.org/10.3345/kjp.2018.61.5.160
  4. N-terminal probrain natriuretic peptide as biomarker for diagnosis of Kawasaki disease vol.13, pp.4, 2015, https://doi.org/10.2217/bmm-2018-0324
  5. B Cells and Antibodies in Kawasaki Disease vol.20, pp.8, 2015, https://doi.org/10.3390/ijms20081834
  6. Antibodies and Immunity During Kawasaki Disease vol.7, pp.None, 2015, https://doi.org/10.3389/fcvm.2020.00094
  7. Kawasaki-like disease in children with COVID-19 vol.40, pp.12, 2015, https://doi.org/10.1007/s00296-020-04701-6